These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32124135)

  • 41. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
    BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
    Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM
    Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.
    Wang JH; Forterre AV; Zhao J; Frimannsson DO; Delcayre A; Antes TJ; Efron B; Jeffrey SS; Pegram MD; Matin AC
    Mol Cancer Ther; 2018 May; 17(5):1133-1142. PubMed ID: 29483213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
    Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
    Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
    Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
    Zhang X; Chen J; Weng Z; Li Q; Zhao L; Yu N; Deng L; Xu W; Yang Y; Zhu Z; Huang H
    Mol Immunol; 2020 Mar; 119():48-58. PubMed ID: 31978707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
    Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
    Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
    Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
    Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
    J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
    Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
    Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro.
    Aoyagi Y; Kuroda M; Asada S; Tanaka S; Konno S; Tanio M; Aso M; Okamoto Y; Nakayama T; Saito Y; Bujo H
    Exp Cell Res; 2012 Jan; 318(1):8-15. PubMed ID: 22020322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
    Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
    Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.